<?xml version='1.0' encoding='utf-8'?>
<document id="26720290"><sentence text="Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors."><entity charOffset="49-57" id="DDI-PubMed.26720290.s1.e0" text="imatinib" /></sentence><sentence text="Imatinib is the standard first-line therapy for metastatic gastrointestinal stromal tumors"><entity charOffset="0-8" id="DDI-PubMed.26720290.s2.e0" text="Imatinib" /></sentence><sentence text=" It has markedly improved the prognosis and outcome of patients affected by gastrointestinal stromal tumors, especially in the case of exon 11 KIT mutations" /><sentence text=" Imatinib-associated adverse events are generally mild to moderate; however, in clinical practice, intolerance caused by chronic toxicities frequently leads to breaks in treatment"><entity charOffset="1-9" id="DDI-PubMed.26720290.s4.e0" text="Imatinib" /></sentence><sentence text=" This is particularly true in elderly patients in whom age, decline in drug metabolism, and polypharmacy, with a possible drug-drug interaction, may influence the tolerability of imatinib"><entity charOffset="179-187" id="DDI-PubMed.26720290.s5.e0" text="imatinib" /></sentence><sentence text=" In the present article, we report our extensive experience with the management of imatinib therapy in a 'real' population, in particular in very elderly patients, discussing whether the use of personalized imatinib dosage could be a safe and advantageous option, enabling continuous administration, thus ensuring effective treatment"><entity charOffset="83-91" id="DDI-PubMed.26720290.s6.e0" text="imatinib" /><entity charOffset="207-215" id="DDI-PubMed.26720290.s6.e1" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.26720290.s6.e0" e2="DDI-PubMed.26720290.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26720290.s6.e0" e2="DDI-PubMed.26720290.s6.e1" /></sentence><sentence text=" Only a few case reports in the literature provide data on outcome with low tailored dosage of imatinib and none of them has been carried out on a Western population"><entity charOffset="95-103" id="DDI-PubMed.26720290.s7.e0" text="imatinib" /></sentence><sentence text=" Here, we report four cases treated with low imatinib dosage as a safe and useful option enabling continued treatment with imatinib, improving tolerance, and maintaining good and lasting disease control"><entity charOffset="45-53" id="DDI-PubMed.26720290.s8.e0" text="imatinib" /><entity charOffset="123-131" id="DDI-PubMed.26720290.s8.e1" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.26720290.s8.e0" e2="DDI-PubMed.26720290.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26720290.s8.e0" e2="DDI-PubMed.26720290.s8.e1" /></sentence><sentence text=" " /></document>